Insider Trading in U.S. Stocks | Inotiv disclosed three insider transactions on February 19

K-LinePoet · 2026-02-23T02:10:50+00:00

Inotiv disclosed insider trading activities on February 19, 2026, including Director Leasure Robert Jr. selling 16,800 shares on February 17, and other executives also conducted sell transactions. Inotiv is an international contract research organization providing drug discovery and development services, headquartered in Indiana.

K-LinePoet

2026-02-23 02:10:50

Abstract generation in progress

On February 19, 2026, Inotiv (NOTV) disclosed three insider trading transactions. Director Leasure Robert Jr. sold 16,800 shares on February 17, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 19, 2026	Director	Leasure Robert Jr.	February 17, 2026	Sell	16,800	0.30	4,963.99
February 19, 2026	Executive	Taylor Beth A.	February 17, 2026	Sell	2,888	0.29	845.90
February 19, 2026	Executive	Sagartz John E.	February 17, 2026	Sell	2,119	0.29	616.21
February 3, 2026	Director	Leasure Robert Jr.	February 2, 2026	Sell	113,300	0.50	57,000
December 2, 2025	Director	Neff R Matthew	December 1, 2025	Sell	2,000	0.89	1,770.60
November 4, 2025	Director	Neff R Matthew	November 3, 2025	Sell	2,000	1.24	2,486.80
October 28, 2025	Director	Neff R Matthew	October 24, 2025	Buy	10,000	1.94	19,400
October 3, 2025	Director	Neff R Matthew	October 1, 2025	Sell	2,000	1.43	2,857.80
September 4, 2025	Director	Neff R Matthew	September 2, 2025	Sell	2,000	1.67	3,337.60
August 4, 2025	Director	Neff R Matthew	August 1, 2025	Sell	2,000	1.91	3,818.00

[Company Information]

Inotiv, Inc. began operations in 1975 under the name Bioanalytical Systems, Inc., which was registered in 1974. In March 2021, the company changed its name to Inotiv, Inc., headquartered in Lafayette, Indiana. Inotiv, Inc. is an international contract research organization providing services for drug discovery and development. Its clients and partners include pharmaceutical, biotechnology, academic, and government institutions. The company leverages innovative technologies and products, along with its commitment to quality, to help clients and partners accelerate the development of safe and effective therapies and maximize their research and development investment returns. The company offers a cost-efficient, scalable alternative to in-house product development plans. It outsources development work and reduces expenses through FDA approval. The company’s revenue comes from sales of its research services and drug development tools, both focused on determining the safety and efficacy of drugs.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.